Affimed in the spotlight (part V)

Evaluating AFM24 monotherapy data and next catalyst

For those just tuning in to our coverage of Affimed (AFMD), you may refer to our previous posts here. Today, Affimed reported AFM24 monotherapy data and it was a disappointment, as we were expecting in our last post.

What AFM24 Mono Showed
Affimed is taking the 480mg dose into Phase 2. This was the 6th Cohort in Phase 1, and showed 2/6 patients had stabl…